Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 2 of 2 entries
Sorted by: Best Match Show Resources per page
Exosomal survivin facilitates vesicle internalization.

Oncotarget

Gonda A, Kabagwira J, Senthil GN, Ferguson Bennit HR, Neidigh JW, Khan S, Wall NR.
PMID: 30405884
Oncotarget. 2018 Oct 09;9(79):34919-34934. doi: 10.18632/oncotarget.26182. eCollection 2018 Oct 09.

Survivin, a member of the inhibitor of apoptosis (IAP) protein family plays a significant role in cell fate and function. It is significantly overexpressed in tumor cells and has been identified in most cancer cell types. A novel extracellular...

Cite
Gonda A, Kabagwira J, Senthil GN, et al. Exosomal survivin facilitates vesicle internalization. Oncotarget. 2018;9(79):34919-34934doi: 10.18632/oncotarget.26182.
Gonda, A., Kabagwira, J., Senthil, G. N., Ferguson Bennit, H. R., Neidigh, J. W., Khan, S., & Wall, N. R. (2018). Exosomal survivin facilitates vesicle internalization. Oncotarget, 9(79), 34919-34934. https://doi.org/10.18632/oncotarget.26182
Gonda, Amber, et al. "Exosomal survivin facilitates vesicle internalization." Oncotarget vol. 9,79 (2018): 34919-34934. doi: https://doi.org/10.18632/oncotarget.26182
Gonda A, Kabagwira J, Senthil GN, Ferguson Bennit HR, Neidigh JW, Khan S, Wall NR. Exosomal survivin facilitates vesicle internalization. Oncotarget. 2018 Oct 09;9(79):34919-34934. doi: 10.18632/oncotarget.26182. eCollection 2018 Oct 09. PMID: 30405884; PMCID: PMC6201849.
Copy Download .nbib Format: NLM
Nanoparticles for Targeting of Prostate Cancer.

Current pharmaceutical design

Yari H, Gali H, Awasthi V.
PMID: 32693761
Curr Pharm Des. 2020;26(42):5393-5413. doi: 10.2174/1381612826666200721001500.

Prostate cancer (PCa) is the leading cause of death by cancer in men. Because of the drastic decline in the survival rate of PCa patients with advanced/metastatic disease, early diagnosis of disease and therapy without toxic side effects is...

Cite
Yari H, Gali H, Awasthi V. Nanoparticles for Targeting of Prostate Cancer. Curr Pharm Des. 2020;26(42):5393-5413doi: 10.2174/1381612826666200721001500.
Yari, H., Gali, H., & Awasthi, V. (2020). Nanoparticles for Targeting of Prostate Cancer. Current pharmaceutical design, 26(42), 5393-5413. https://doi.org/10.2174/1381612826666200721001500
Yari, Hooman, et al. "Nanoparticles for Targeting of Prostate Cancer." Current pharmaceutical design vol. 26,42 (2020): 5393-5413. doi: https://doi.org/10.2174/1381612826666200721001500
Yari H, Gali H, Awasthi V. Nanoparticles for Targeting of Prostate Cancer. Curr Pharm Des. 2020;26(42):5393-5413. doi: 10.2174/1381612826666200721001500. PMID: 32693761.
Copy Download .nbib Format: NLM
Showing 1 to 2 of 2 entries